Scandal-plagued Salix said to consider a sale

Salix Pharmaceuticals ($SLXP), marred by an embarrassing inventory scandal, has hired an investment bank to help it find some strategic alternatives, Reuters reports, including an outright sale. The company has watched its shares slip since disclosing in November that its sales expectations were inflated by miscounted drug stockpiles, a revelation that reportedly scared off would-be acquirer Allergan and led CEO Carolyn Logan to step down earlier this month. News

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.